Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p class="first" id="d5359538e7097">Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. </p>

Related collections

Author and article information

Journal

Title: JAMA

Abbreviated Title: JAMA

Publisher: American Medical Association (AMA)

ISSN (Print): 0098-7484

Publication date (Electronic): September 02 2020

Affiliations

[1 ]The Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

[2 ]The UPMC Health System Office of Healthcare Innovation, Pittsburgh, Pennsylvania

[3 ]Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands

[4 ]Intensive Care Center, University Medical Center Utrecht, Utrecht, the Netherlands

[5 ]Division of Anaesthetics, Pain Medicine and Intensive Care Medicine, Department of Surgery and Cancer, Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom

[6 ]Intensive Care Unit, Raymond Poincaré Hospital (AP-HP), Paris, France

[7 ]Simone Veil School of Medicine, University of Versailles, Versailles, France

[8 ]University Paris Saclay, Garches, France

[9 ]Intensive Care Department, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, King Abdulaziz Medical City, Riyadh, Saudi Arabia

[10 ]Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

[11 ]Berry Consultants LLC, Austin, Texas

[12 ]Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Ontario, Canada

[13 ]Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands

[14 ]Bristol Royal Informatory, Bristol, United Kingdom

[15 ]University of Bristol, Bristol, United Kingdom

[16 ]Center for Clinical Studies and Center for Sepsis Control and Care (CSCC), Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany

[17 ]Global Coalition for Adaptive Research, San Francisco, California

[18 ]Helix, Monash University, Melbourne, Victoria, Australia

[19 ]Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, Melbourne, Victoria, Australia

[20 ]Australian and New Zealand Intensive Care Research Centre, School of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

[21 ]Department of Medical Microbiology, Amsterdam University Medical Center, University of Amsterdam, the Netherlands

[22 ]NHS Blood and Transplant, Bristol, United Kingdom

[23 ]Transfusion Medicine, Medical Sciences Division, University of Oxford, Oxford, United Kingdom

[24 ]Department of Microbiology, Antwerp University Hospital, Antwerp, Belgium

[25 ]Network for Improving Critical Care Systems and Training, Colombo, Sri Lanka

[26 ]Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand

[27 ]Intensive Care Unit, Princess Alexandra Hospital, Brisbane, Queensland, Australia

[28 ]Université de Sherbrooke, Sherbrooke, Quebec, Canada

[29 ]Cardiac Intensive Care Unit, Peter Munk Cardiac Centre, University Health Network, Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada

[30 ]School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia

[31 ]Interdepartmental Division of Critical Care, University of Toronto, Toronto, Ontario, Canada

[32 ]Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, United Kingdom

[33 ]Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland, New Zealand

[34 ]The Health Research Council of New Zealand, Wellington, New Zealand

[35 ]Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

[36 ]Clinical Trials Unit, Intensive Care National Audit & Research Centre (ICNARC), London, United Kingdom

[37 ]University of British Columbia School of Medicine, Vancouver, Canada

[38 ]Department of Anesthesia and Intensive Care, St Vincent’s University Hospital, Dublin, Ireland

[39 ]School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland

[40 ]Department of Intensive Care, Alfred Health, Melbourne, Victoria, Australia

[41 ]School of Nursing, University of Auckland, Auckland, New Zealand

[42 ]Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands

[43 ]Southside Clinical Unit, Princess Alexandra Hospital, Brisbane, Queensland, Australia

[44 ]The George Institute for Global Health, Sydney, Australia

[45 ]Department of Medicine, Critical Care and Hematology/Medical Oncology, University of Manitoba, Winnipeg, Manitoba, Canada

[46 ]Department of Emergency Medicine, Harbor-UCLA Medical Center, Torrance, California

[47 ]Department of Emergency Medicine, David Geffen School of Medicine at University of California, Los Angeles

[48 ]Department of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand

[49 ]St John of God Hospital, Subiaco, Western Australia, Australia

Article

DOI: 10.1001/jama.2020.17022

PMC ID: 7489418

PubMed ID: 32876697

SO-VID: 849e36c9-f563-4808-a70d-8568182e4e0a

History

Data availability:

Comments

Comment on this article

scite_

Cited by 408

See all cited by

- Version 1

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 : The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

Read this article at